Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids

Joseph V. Pergolizzi, Sumedha A. Labhsetwar, R. Amy Puenpatom, Rami Ben-Joseph, Robert Ohsfeldt, Kent H. Summers

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Patients with osteoarthritis (OA) taking at least one CYP450-metabolized opioid concurrently with another CYP450-metabolized medication experience a drug-drug exposure (DDE), which puts them at risk of a pharmacokinetic drug-drug interaction (PK DDI). This study compared patients with and without such an incident DDE to determine healthcare utilization and associated payments. Using a retrospective database analysis, the impact of DDEs was evaluated in terms of associated clinical events, healthcare services utilization (office visits, outpatient visits, ED visits, hospitalization), and payments in patient populations based on age (those under age 65 and those 65years of age and older), during the 6months after exposure. DDE patients had significantly more inpatient hospitalizations than no-DDE patients. Mean total payments at 6months were significantly higher for both younger and older patients with DDE compared to similar patients without DDE ($9,469, SD=$12,192 vs. $8,382, SD=$14,078, respectively, for younger patients, resulting in a difference of $1,087, P

Original languageEnglish (US)
Pages (from-to)33-44
Number of pages12
JournalPain Practice
Issue number1
StatePublished - Jan 2012


  • Analgesics
  • Narcotics
  • Opioid Analgesics
  • Opioid Arthritis
  • Opioids
  • Pharmacologic Actions
  • Therapeutics

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine


Dive into the research topics of 'Economic impact of potential drug-drug interactions among osteoarthritis patients taking opioids'. Together they form a unique fingerprint.

Cite this